Johnson & Johnson JNJ
Stock research in plain language · As of Oct 04, 2026 · updated once a week, after the trading week closes
What the company does
Johnson & Johnson is a mega-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $617.0B, based in the USA.
It employs about 138,200 people and has been listed since Sep 24, 1944.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Cheap or expensive? priced in line with its group
Its price-to-earnings (P/E) is 29.7 versus 37.7 for 4 direct peers — priced in line with its group.
Revenue is growing 7% versus the same quarter last year.
On analysts' next-year forecasts the multiple drops to 21.0 — they expect higher earnings.
The average analyst price target is 279.27, 9% above the current price (their view, not ours).
The stock sits at 75% of its one-year range (0% = the low, 100% = the high).
The risks
- • Quarterly report in 9 days (2026-10-13) — a day the stock can move a lot.
Strengths
- ✅ Profitable — 22 of every 100 dollars of revenue stays as profit.
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Most analysts rate it buy (16 vs 1).
- ✅ Pays a dividend (2.0% a year).
What changed this week
Over the past week the stock fell 5.6% (for comparison: S&P 500 -0.2%, sector ETF XLV -2.6%).
This week's news
- What is Progressive’s (PGR) Economic Moat, and is it Widening or Narrowing? finance.yahoo.com · 2026-10-04
- AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy? finance.yahoo.com · 2026-10-04
- Johnson & Johnson (JNJ) Reports Sustained Phase 3 Skin Clearance For ICOTYDE finance.yahoo.com · 2026-10-03
- Why Medtronic’s $4 Billion MiniMed Exchange Offer Is Losing Its Allure finance.yahoo.com · 2026-10-02
- Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says finance.yahoo.com · 2026-10-02
- Johnson & Johnson (JNJ) IMAAVY Data Puts Its Undervalued Narrative Back In Focus finance.yahoo.com · 2026-10-02
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.